ThinkEquity,
A Division of Fordham Financial Management, Inc
17 State Street, 22nd Floor
New York, New York 10004
November 12, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Inhibikase Therapeutics, Inc. (the “Company”) | |
|
Registration Statement on Form S-1, as amended (the “Registration Statement”) File No. 333-240036 |
Ladies and Gentlemen:
On November 6, 2020, ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), as representative of the underwriters of the offering, joined in the request of the Company that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so as to permit it to become effective on Tuesday, November 10, 2020, at 5:00 p.m. (Eastern Time), or as soon thereafter as practicable. The undersigned, on behalf of ThinkEquity, hereby withdraws such request.
| Very truly yours, | |||
| ThinkEquity, | |||
| a division of Fordham Financial Management, Inc. | |||
| By: | /s/ Eric Lord | ||
| Name: | Eric Lord | ||
| Title: | Head of Investment Banking | ||
| cc: | Leslie Marlow, Esq. |
Patrick J. Egan, Esq.